AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05976100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
Study NCT05976100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
Study NCT01488773 — intervention group
Intervention type: DRUG
Intervention: first prescription of montelukast
Description: The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
Study NCT01488773 — intervention group
Intervention type: DRUG
Intervention: first prescription of salmeterol
Description: The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
Study NCT01897428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test-Bepotastine salicylate 9.64 mg
Study NCT01897428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference-bepotastine besilate 10 mg
Study NCT00495807 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: No Words
Description: Without any words was given during pain management
Study NCT00495807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive words
Description: Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
Study NCT00495807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partially Negative Words
Description: Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
Study NCT00495807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Totally Negative Words
Description: Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
Study NCT02814344 — intervention group
Intervention type: DEVICE
Intervention: Electrohysterography
Study NCT01973998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: PDE4 inhibitor
Study NCT01973998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance.
Study NCT00756990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Naltrexone
Description: 228mg of injectable naltrexone
Study NCT02672462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio frequency renal denervation system (Golden Leaf GL-06E15A)
Study NCT01012765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI
Study NCT02848807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NUTRIDRINK Compact Protein
Description: high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
Study NCT01113723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscope
Description: Fiberoptic bronchoscope device
Study NCT01113723 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CMAC
Description: CMAC Device
Study NCT01378442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fitness training program
Description: Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style.
Study NCT02186665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol ointment
Study NCT02186665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Study NCT02712528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil-based
Study NCT02712528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane-sufentanil balanced
Study NCT02523378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Edmonton Symptom Assessment Scale
Description: Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
Study NCT02523378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
Study NCT05612334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)
Description: the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
Study NCT05612334 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)
Description: the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
Study NCT01178099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Oral, daily for 12 days
Study NCT03650699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electropalatography Biofeedback Training
Description: The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
Study NCT00697632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: Oral daily administration without interruption
Study NCT05652712 — intervention group
Intervention type: DRUG
Intervention: Toripalimab
Description: Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Study NCT00870987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine prime
Description: 2 mg total dose (1 mg per construct in a volume of 1 mL)
Study NCT00870987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus type 5 vaccine boost
Description: 2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
Study NCT03694431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tech-supported HBPC
Description: Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
Study NCT03694431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard HBPC
Description: Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
Study NCT03263572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT03263572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally via spinal tap
Study NCT03263572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally via spinal tap
Study NCT03263572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study NCT02154256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing incentives
Description: Offer incentives that increase over time.
Study NCT02154256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decreasing incentives
Description: offer incentives that decrease over time
Study NCT00982657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Study NCT00982657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Study NCT02154256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stable incentives
Description: offer incentives that are stable over time, but higher than usual care
Study NCT01857297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzira® vaccine
Study NCT03657849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS TBNA
Description: All patients undergo EBUS TBNA with two needle sizes
Study NCT03257683 — intervention group
Intervention type: DRUG
Intervention: Ranolazine
Description: Study group will receive additional therapeutic dosing of drug.
Study NCT00048347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVONEX
Description: 30µg IM every week for 12 weeks
Study NCT01521663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX159
Study NCT00982657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Study NCT00982657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Study NCT00982657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg sunitinib daily (4 out of 6 weeks)
Study NCT01326845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT02810925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENS T6
Description: Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
Study NCT02810925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENS T6
Description: Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
Study NCT02810925 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TENS T11/T12
Description: Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
Study NCT02810925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric 1200 Kcal/day diet
Description: Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
Study NCT00383994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
Study NCT00383994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
Study NCT01813162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 1% gel
Study NCT01813162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Study NCT01813162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal product
Study NCT01813162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal product
Study NCT02008162 — intervention group
Intervention type: DRUG
Intervention: Bronchodilators
Description: Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
Study NCT03674866 — intervention group
Intervention type: DRUG
Intervention: Insulin degludec
Description: Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
Study NCT01521663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04254601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B.
Description: NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)
Study NCT04254601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical erythromycin cream 2% (Akne-Mycin- Egypt)
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Study NCT00318032 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: multi-factorial intervention
Study NCT03138265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT Device: ergometer
Description: Supervised exercise training.
Study NCT01319539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT04254601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical erythromycin cream 2% (Akne-Mycin- Egypt)
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Study NCT03828851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary care - Activities of Daily Living
Description: Home-based ADL training.
Study NCT01478724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk proteins fraction
Description: capsules, one per day, 24 months
Study NCT01478724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk proteins fraction
Description: capsules, one per day, 24 months
Study NCT04043650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartSteps
Description: HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
Study NCT02022163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of H7 VLP vaccine + Alhydrogel
Description: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
Study NCT02022163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Med dose of H7 VLP vaccine + Alhydrogel
Description: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
Study NCT02022163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H7 VLP vaccine + Alhydrogel
Description: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
Study NCT02022163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H7 VLP vaccine
Description: High dose of H7 VLP vaccine, 2 doses given 21 days apart
Study NCT02022163 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 doses given 21 days apart
Study NCT04093440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lifestyle modification
Description: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
Study NCT03213834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest thoracoscopy
Description: Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
Study NCT03213834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest fibrinolytic therapy
Description: A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Study NCT03213834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tPA
Description: tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Study NCT03213834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNase
Description: DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Study NCT03570359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1A
Description: Interferon Beta-1A via inhalation
Study NCT03570359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via inhalation
Study NCT01319539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01319539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01319539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02190994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: used intravenously
Study NCT00892775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)
Description: Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
Study NCT00892775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 208136, new formulation
Description: Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
Study NCT02190994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: used as tablet form
Study NCT01418066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayurvedic Herbs
Description: A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
Study NCT01418066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
Study NCT03430232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
Study NCT03430232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324 Dose Level 1
Description: Short infusion of a solution for intravenous administration